27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.
ATTRACTnet was developed in an internal test set of 799 patients (mean [SD] age, 75.1 [11.1] years; 516 [64.7%] male and 283 [35.3%] female) using 5-fold cross-validation with an additional external test set of 422 patients. 5 key findings →
Design: open-label trial Participants: 799 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Age, education level, number of pain sites, pain duration, pain level, depression and sleep quality were risk factors of MCI in older patients with chronic pain. 5 key findings →
Design: longitudinal study Participants: 612 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Distinct gut microbial compositions are associated with dementia. 2 key findings →
Design: systematic review Participants: 896 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Early detection of Alzheimer's disease (AD) is critical yet challenging, particularly in younger individuals. 1 key finding →
Design: longitudinal study Participants: 120 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The BHA has excellent performance characteristics in detecting cognitive impairment including dementia and MCI in a Hispanic population in Cuba and outperformed the MoCA. 2 key findings →
Design: cross-sectional Participants: 146 Evidence: low
Full summary, score breakdown and related studies → Original source
Our findings indicate that AD patients present impairments in some key functional abilities, such as gait, turning and sitting, sit to stand, and reaction time, both in mild and moderate AD. 4 key findings →
Design: cross-sectional Participants: 22 Evidence: low
Full summary, score breakdown and related studies → Original source
These findings show how online testing can now be deployed in patients with AD to measure cognitive function effectively and related to blood biomarkers of the disease. 4 key findings →
Participants: 46 Evidence: low
Full summary, score breakdown and related studies → Original source
These findings suggest that the ALLFTD-mApp study protocol is feasible and acceptable for remote FTD research. 3 key findings →
Participants: 101 Evidence: low
Full summary, score breakdown and related studies → Original source
The best predictor of CDR at 36 months was M, a DCB reflecting recall ability (area under the curve = 0.84), outperforming traditional scores. 5 key findings →
Participants: 330 Evidence: low
Full summary, score breakdown and related studies → Original source
Average compliance by time of day ranged from 90.2% for morning sessions, to 77.9% for afternoon sessions, and 84.4% for evening sessions. 5 key findings →
Participants: 120 Evidence: low
Full summary, score breakdown and related studies → Original source
Age- and sex-specific reference values were generated for three DANA tasks. 5 key findings →
Participants: 932 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Our results demonstrated that dual-task could significantly improve the ability to predict cognitive impairment based on gait parameters such as gait speed (GS) and stride length (SL). 5 key findings →
Participants: 38 Evidence: low
Full summary, score breakdown and related studies → Original source
The search for early biomarkers of mild cognitive impairment (MCI) has been central to the Alzheimer's Disease (AD) and dementia research community in recent years. 1 key finding →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Digital cognitive testing using online platforms has emerged as a potentially transformative tool in clinical neuroscience. 3 key findings →
Participants: 325 Evidence: low
Full summary, score breakdown and related studies → Original source
Translating human genetic findings (genome-wide association studies [GWAS]) to pathobiology and therapeutic discovery remains a major challenge for Alzheimer's disease (AD). 2 key findings →
Design: case-control study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Despite subjects with Dominantly-Inherited Alzheimer's Disease (DIAD) represent less than 1% of all Alzheimer's Disease (AD) cases, the Dominantly Inherited Alzheimer Network (DIAN) initiative constitutes a strong impact in the understanding of AD disease course with special emphasis on the presyptomatic disease phase. 1 key finding →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Although a small-scale study (n = 60), it suggests that older adults operate in larger geographic spaces than in the areas where they reside. 5 key findings →
Design: cross-sectional Participants: 60 Evidence: moderate
Full summary, score breakdown and related studies → Original source
The implementation represented radical innovation and required far more resources than the incremental changes anticipated by the participants. 3 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Our findings suggest that dCDT is a suitable screening tool to identify early cognitive dysfunction. 1 key finding →
Participants: 381 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
These results revealed a universal applicability of the "A/T/N" framework in a Chinese population and established an optimal diagnostic model consisting of cost-effective and non-invasive approaches for diagnosing AD. 2 key findings →
Participants: 411 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Our results demonstrate that unsupervised digital memory assessments might be used for diagnosis and prognosis in Alzheimer's disease, potentially in combination with plasma biomarkers. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Dementia is one of the most common neurological syndromes in the world. 1 key finding →
Participants: 1,315 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Despite the increasing incidence and high morbidity associated with dementia, a simple, non-invasive, and inexpensive method of screening for dementia is yet to be discovered. 4 key findings →
Participants: 121 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Early diagnosis of Alzheimer's disease plays a pivotal role in patient care and clinical trials. 4 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
We assessed the impact of amyloid precursor protein (APP) gene locus duplications in early onset Alzheimer's disease in a Dutch population-based sample. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
10 of the 1,109 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →